Autoimmune hemolytic anemia screening: Difference between revisions
Jump to navigation
Jump to search
Iqra Qamar (talk | contribs) |
Iqra Qamar (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Screening== | ==Screening== | ||
Screening for autoimmune hemolytic anemia is not currently done routinely. The incidence of autoimmune hemolytic anemia is low enough such that screening measures are not indicated. However, screening is done for other conditions associated with hemolytic anemia, such as sickle cell disease.<ref name="pmid27785945">{{cite journal| author=Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M et al.| title=Emerging point-of-care technologies for sickle cell disease screening and monitoring. | journal=Expert Rev Med Devices | year= 2016 | volume= 13 | issue= 12 | pages= 1073-1093 | pmid=27785945 | doi=10.1080/17434440.2016.1254038 | pmc=5166583 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27785945 }} </ref> One important manifestation of sickle cell disease is | * Screening for autoimmune hemolytic anemia is not currently done routinely. | ||
* The incidence of autoimmune hemolytic anemia is low enough such that screening measures are not indicated. | |||
* However, screening is done for other conditions associated with hemolytic anemia, such as [[Sickle-cell disease|sickle cell disease]].<ref name="pmid27785945">{{cite journal| author=Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M et al.| title=Emerging point-of-care technologies for sickle cell disease screening and monitoring. | journal=Expert Rev Med Devices | year= 2016 | volume= 13 | issue= 12 | pages= 1073-1093 | pmid=27785945 | doi=10.1080/17434440.2016.1254038 | pmc=5166583 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27785945 }} </ref> | |||
* One important manifestation of sickle cell disease is hyperhemolytic crisis, in which there is massive [[hemolysis]]. | |||
* The United States and the United Kingdom have formal screening processes in place for sickle cell disease for newborns. | |||
* Screening for sickle cell disease can prevent early childhood morbidity and mortality. | |||
* Less developed countries, such as countries in Africa, do not have formal screening measures for [[sickle cell disease]] in place.<ref name="pmid27785945">{{cite journal| author=Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M et al.| title=Emerging point-of-care technologies for sickle cell disease screening and monitoring. | journal=Expert Rev Med Devices | year= 2016 | volume= 13 | issue= 12 | pages= 1073-1093 | pmid=27785945 | doi=10.1080/17434440.2016.1254038 | pmc=5166583 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27785945 }} </ref> | |||
==References== | ==References== | ||
Revision as of 20:29, 22 May 2018
|
Autoimmune hemolytic anemia Microchapters |
|
Differentiating Autoimmune hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune hemolytic anemia screening On the Web |
|
American Roentgen Ray Society Images of Autoimmune hemolytic anemia screening |
|
Directions to Hospitals Treating Autoimmune hemolytic anemia |
|
Risk calculators and risk factors for Autoimmune hemolytic anemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2], Irfan Dotani [3]
Overview
Screening for autoimmune hemolytic anemia is not currently done routinely.
Screening
- Screening for autoimmune hemolytic anemia is not currently done routinely.
- The incidence of autoimmune hemolytic anemia is low enough such that screening measures are not indicated.
- However, screening is done for other conditions associated with hemolytic anemia, such as sickle cell disease.[1]
- One important manifestation of sickle cell disease is hyperhemolytic crisis, in which there is massive hemolysis.
- The United States and the United Kingdom have formal screening processes in place for sickle cell disease for newborns.
- Screening for sickle cell disease can prevent early childhood morbidity and mortality.
- Less developed countries, such as countries in Africa, do not have formal screening measures for sickle cell disease in place.[1]
References
- ↑ 1.0 1.1 Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M; et al. (2016). "Emerging point-of-care technologies for sickle cell disease screening and monitoring". Expert Rev Med Devices. 13 (12): 1073–1093. doi:10.1080/17434440.2016.1254038. PMC 5166583. PMID 27785945.